AMGEN REPORTS REVENUES ROSE 18 PERCENT IN 1995.Byline: Deborah Adamson Daily News Staff Writer Amgen Inc. in Thousand Oaks Thousand Oaks, residential city (1990 pop. 104,352), Ventura co., S Calif., in a farm area; inc. 1964. Avocados, citrus, vegetables, strawberries, and nursery products are grown. reported a 23 percent increase in comparable earnings and an 18 percent gain in revenues for fiscal year 1995. The biotechnology firm credits its double-digit gains to the continued success of the Epogen and Neupogen products. Epogen treats anemia related to kidney disease Kidney Disease Definition Kidney disease is a general term for any damage that reduces the functioning of the kidney. Kidney disease is also called renal disease. and Neupogen is a stimulator of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . "The increase in our revenues was exclusively due to the growth in product sales. Both had continued strong growth," said spokesman David Kaye David V. Hope (born 14 October 1964), known professionaly as David Kaye, is a Canadian actor who is better known and revered for his work as a voice actor. Career . "In terms of earnings, in addition to increased product sales, there was renewed strong expense management." Amgen Inc.'s earnings were in line with expectations, said John Wong, an analyst at Van Kasper & Co. in Brentwood. The stock closed at 60-1/8 Wednesday, down 1 3/16. Amgen's earnings were announced after the market closed. For the year ended Dec. 31, net income was $537.7 million ($1.92 a share), which includes a fourth quarter charge of $10 million (2 cents) for a license fee to NPS NPS National Park Service NPS Naval Postgraduate School NPS Net Promoter Score (customer management) NPS Non-Point Source pollution NPS Native Plant Society NPS Norfolk Public Schools (Virginia) Pharmaceuticals. Amgen plans to develop and commercialize an NPS product that treats a thyroid thyroid /thy·roid/ (thi´roid) 1. the thyroid gland; see under gland. 2. pertaining to the thyroid gland. 3. scutiform. 4. gland condition related to kidney disease. In fiscal 1994, Amgen had a comparable income of $436 million ($1.56), excluding a one-time $116 million charge for the purchase of Synergen. Revenues were $1.94 billion vs. $1.65 billion. For the fourth quarter, net income was $145.6 million (52 cents a share) compared with $121 million (44 cents) a year ago, excluding the Synergen charge. Revenue was $513.5 million vs. $442.9 million. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion